admin
February 23, 2026
Short answer: the real difference between 510(k), De Novo, and PMA is not speed. It is risk tolerance. Each pathway reflects how much uncertainty the U.S. Food and Drug Administration is willing to accept—and how much evidence they require to reduce that uncertainty.
February 20, 2026
Short answer: an FDA regulatory pathway is not just a compliance decision. It is a portfolio risk signal. For investors, the difference between 510(k), De Novo, […]
February 19, 2026
Direct answer: choosing the wrong FDA pathway does not just delay your launch. It can add millions in cost, years in delay, and materially reduce company valuation. Most pathway mistakes happen early—when teams assume a 510(k) is viable without fully pressure-testing risk, intended use, or technological differences.
February 18, 2026
Short answer: incorrect FDA pathway assumptions don’t usually fail at the beginning. They fail when investors start asking hard questions. Early on, optimism hides regulatory gaps. During investor diligence, those gaps get exposed. That’s because regulatory pathway decisions—510(k), De Novo, or PMA—are not just technical. They define your timeline, capital needs, and exit strategy.
